NIH Begins Enrollment For Late-Stage Study Of Siga Technologies’ Antiviral Against Monkeypox

Reuters (9/9, Mahobe) reported the NIH “said on Friday it had started enrolling [patients with monkeypox] in a late-stage study testing Siga Technologies Inc’s antiviral pill Tpoxx [tecovirimat] against the disease.” The agency “aims to enroll more than 5...